1 day Ago By ABMN Staff
Renaissance Technologies LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Free Report ) by 89.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor owned 26,110 shares of the biopharmaceutical company’s stock after selling 229,170 shares during the quarter. Renaissance Technologies LLC’s holdings in Halozyme Therapeutics were worth $1,248,000 as of its most recent filing with the Securities and Exchange Commission. Other institutional investors have also recently added to or reduced their stakes in the company.
Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter.
Louisiana State Employees Retirement System raised its holdings in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock valued at $1,688,000 after buying an additional 200 shares during the period.
State of New Jersey Common Pension Fund D lifted its position in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after acquiring an additional 302 shares in the last quarter.
Parkside Financial Bank & Trust boosted its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the period.
Finally, Nations Financial Group Inc. IA ADV grew its position in Halozyme Therapeutics by 2.4% in the fourth quarter.
Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 328 shares in the last quarter. 97.
79% of the stock is owned by hedge funds and other institutional investors. Insider Buying and Selling at Halozyme Therapeutics In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.
30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.
30. The trade was a 11.46 % decrease in their position.
The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th.
The shares were sold at an average price of $58.28, for a total value of $98,901.16.
Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.
97 % decrease in their position. The disclosure for this sale can be found here . Insiders sold a total of 26,697 shares of company stock worth $1,558,052 over the last ninety days.
Company insiders own 2.40% of the company’s stock. Halozyme Therapeutics Stock Performance Halozyme Therapeutics ( NASDAQ:HALO – Get Free Report ) last posted its quarterly earnings results on Tuesday, February 18th.
The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.
02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.
78%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.
74 million. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.
73 EPS for the current year. Analysts Set New Price Targets A number of research firms have recently commented on HALO. HC Wainwright reissued a “buy” rating and set a $72.
00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $55.
00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.
00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $75.
00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.
00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.
com, the company presently has an average rating of “Moderate Buy” and an average price target of $62.89. View Our Latest Report on HALO About Halozyme Therapeutics ( Free Report ) Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Further Reading Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc.
( NASDAQ:HALO – Free Report ). Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
